Investigational device can discriminate between normal cells, cancerous cells in sputum with 90% sensitivity and almost 100% specificity, according to its manufacturer, VisionGate, Inc. Bob Finn Global Medical News Network (GMNN) Report of the World Conference on Lung Cancer in San Francisco.
No comments:
Post a Comment